Research location
Hamilton
Waikato Region, New Zealand
Advertisement
Research activity in Hamilton
Waikato Region, New ZealandCureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 30 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hamilton
30 linked trials · page 1 of 1An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07365332 · 2026-04-23 · 1 site observation
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) TrialNCT05072314 · 2022-07-27 · 1 site observation
RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · 2021-05-12 · 1 site observation
RECRUITING
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesNCT07284875 · 2025-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.NCT07234864 · 2025-11-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)NCT04811092 · 2022-03-18 · 1 site observation
TERMINATED
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
SER150 vs Placebo in Diabetic Kidney DiseaseNCT04881123 · 2021-08-18 · 1 site observation
COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · 2021-02-23 · 1 site observation
COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyNCT03860935 · 2019-03-19 · 1 site observation
COMPLETED
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisNCT02049138 · 2014-01-24 · 1 site observation
COMPLETED
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CancerNCT02066961 · 2013-12-31 · 1 site observation
COMPLETED
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)NCT01970878 · 2013-11-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 1 site observation
COMPLETED
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)NCT01854645 · 2013-05-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01085045 · 2010-03-01 · 1 site observation
COMPLETED
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's DiseaseNCT00660673 · 2009-11-13 · 1 site observation
COMPLETED
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD PatientsNCT00567398 · 2008-04-01 · 1 site observation
COMPLETED
Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes MellitusNCT00453375 · 2006-10-01 · 1 site observation
COMPLETED
Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) StudyNCT00745043 · 2005-05-01 · 1 site observation
COMPLETED
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerNCT00038467 · 1998-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.